Home/Pipeline/R-One/R-One+

R-One/R-One+

Percutaneous Coronary Intervention (PCI) for coronary artery disease

ApprovedActive

Key Facts

Indication
Percutaneous Coronary Intervention (PCI) for coronary artery disease
Phase
Approved
Status
Active
Company

About Robocath

Robocath is a pioneering private company in the vascular robotics space, with its CE-marked R-One/R-One+ platform commercially available in Europe, Africa, and China. The company focuses on improving procedural precision and clinician safety from radiation during percutaneous coronary interventions (PCI). With over 70 employees and a foundation in unique bionic technology, Robocath aims to become a global leader in the digital evolution of interventional cardiology and vascular medicine.

View full company profile

Therapeutic Areas